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1  |  INTRODUC TION
Over 10% of people living with HIV (PLWH) in West Africa also have 
chronic hepatitis B virus (HBV) infection, the leading cause of liver 
cirrhosis and cancer in the region.1 HIV infection has a profound 
impact on the natural history of HBV, including the acceleration of 
the progression to end- stage liver disease and the increase in liver- 
related mortality.2,3 Tenofovir- containing antiretroviral therapy 
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Abstract
Chronic hepatitis B virus (HBV) infection affects >10% of the general population and 
is the leading cause of liver cirrhosis and cancer in West Africa. Despite current rec-
ommendations, HBV is often not tested for in clinical routine in the region. We in-
cluded all people living with HIV (PLWH) in care between March and July 2019 at 
Fann University Hospital in Dakar (Senegal) and proposed hepatitis B surface antigen 
(HBsAg) test to those never tested. All HBsAg- positive underwent HIV and HBV viral 
load (VL) and liver stiffness measurement. We evaluated, using logistic regression, 
potential associations between patient characteristics and (a) HBV testing uptake; 
(b) HIV/HBV co- infection among individual HBsAg tested. We determined the pro-
portion of co- infected who had HBV DNA >20 IU/ml on ART and sequenced HBV 
polymerase in those with HBV replication.of 1076 PLWH in care, 689 (64.0%) had 
never had an HBsAg test prior to our HBV testing intervention. Women and individu-
als >40 years old were less likely to have been previously tested. After HBV test-
ing intervention,107/884 (12.1%) PLWH were HBsAg- positive. Seven of 58 (12.1%) 
individuals newly diagnosed with HIV/HBV co- infection had a detectable HBV VL, 
of whom five were HIV- suppressed. Two patients on ART including 3TC and AZT as 
backbone showed the presence of the triple resistance mutation 180M/204I/80V. 
In this Senegalese urban HIV clinic, the majority of patients on ART had never been 
tested for HBV infection. One in ten co- infected individuals had a detectable HBV VL 
despite HIV suppression, and 8% were not receiving a TDF- containing regimen.
K E Y W O R D S
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(ART) leads to HBV viral suppression in more than 80% of HIV/HBV- 
co- infected individuals and reduces the progression of liver fibrosis 
and the risk of hepatocellular carcinoma (HCC).4– 6 Considering its 
clinical benefits and high genetic barrier to resistance, tenofovir, ei-
ther as tenofovir disoproxil fumarate (TDF) or tenofovir alafenamide 
(TAF), should always be included in the ART regimen of HIV/HBV- 
co- infected individuals, provided there is no contraindication.
Despite international recommendations, the uptake of system-
atic HBV testing among PLWH has been generally poor in sub- 
Saharan Africa.7 This is problematic for several reasons: As tenofovir 
should be included in the ART regimen in the presence of HBV infec-
tion, knowledge of the individual hepatitis B surface antigen (HBsAg) 
status is key in informing the prescription of optimal ART for each 
patient, including second- line and third- line treatment regimens.8 
HBV testing among PLWH is also required to identify those who 
will need a comprehensive liver disease assessment, including the 
measurement of liver fibrosis and HCC surveillance. In addition, the 
systematic testing for HBsAg allows health care providers to offer 
proper counselling on measures to reduce HBV transmission and 
screening of household members.9
We aimed to investigate predictors of HBV testing among PLWH 
in care at a referral HIV outpatient clinic in Senegal and to evaluate 
their HBV infection status by implementing a simple and system-
atic HBV testing intervention. We hypothesized that detecting and 
characterizing HBV infection would allow the improvement of HBV 
management in this patient population.
2  |  MATERIAL S AND METHODS
2.1  |  Study setting
We conducted a cross sectional study at the « Service des Maladies 
Infectieuses et Tropicales/Centre Régional de Recherche et de 
Formation à la Prise en Charge clinique de Fann» (SMIT/CRCF), an 
urban adult HIV treatment centre in Dakar, Sénégal. This clinic has 
been one of the several referral centres for HIV management in 
Senegal since 1998. Since the publication of the first ART recom-
mendations in 2002, Senegal has been adapting its recommenda-
tions in accordance with WHO protocols. Until 2013, recommended 
initial ART combined two nucleos(t)ide reverse transcriptase inhibi-
tors (NRTI), generally lamivudine (LAM) and zidovudine (AZT), and 
one non- nucleoside reverse transcriptase inhibitor (NNRTI). In 2013 
the Senegalese ART guidelines included the use of TDF alongside 
LAM or emtricitabine (FTC) as part of the preferred first- line back-
bones, in line with WHO recommendations.8,10 However, switch-
ing patients with virological suppression to a TDF- based regimen 
was not a priority. As part of routine clinical care, all PLWH initiat-
ing ART undergo clinical and laboratory visits at day 1, 7, 14, 30, 
followed by quarterly visits. CD4 cell counts are measured every 
6 months and HIV- 1 viral load (VL) annually. This study was part of 
a larger research programme, SEN- B, which aims at evaluating the 
determinants of HBV ‘functional cure’ and liver- related outcomes 
among HIV/HBV- co- infected and HBV mono- infected individuals in 
Senegal.
2.2  |  Study participants and data
All PLWH in routine clinical care at the SMIT/CRCF as of January 
2019 were considered for participation in the study. We used the 
centralized database from the Programme National de la Lutte con-
tre le SIDA and medical records to identify the past availability of 
HBsAg test results. Individuals without a recorded HBsAg test result 
were identified and offered voluntary testing for HBV at the next 
scheduled follow- up visit during the study period (March- July 2019). 
The following data were retrieved from the clinical chart of all indi-
viduals: (a) demographic and clinical characteristics: age, sex, marital 
status, employment category, date of first positive HIV test, date of 
ART initiation and date and result of HBV, (b) stage of HIV disease: 
WHO stage, CD4+ cell counts and HIV- 1 VL, and prior AIDS defining 
illnesses; (c) treatment history: prior and current ART and reason for 
treatment changes (eg treatment failure, adverse events).
2.3  |  Study procedures and laboratory 
measurements
HBsAg testing was performed using a one- step lateral flow assay 
rapid test (NOVATest®). NOVATest® (Atlas Link Biotech– ISO 
13485) One- Step Hepatitis B Virus Surface Antibody (HBsAg) 
Test Kit is a CE- marked (CE 2265), rapid immunochromatographic 
in vitro assay for the detection of HBsAg in human serum samples. 
In a validation study in Senegal using the Elecsys® HBsAg II test 
(Cobas e- 411, Roche Diagnostics) as gold standard, the sensitivity 
of NOVATest® was 89.5% and its specificity 100%.11 All individu-
als with a positive HBsAg test result between March and July 2019 
were offered additional laboratory and transient elastography meas-
urements, and samples were stored for viral sequencing. We per-
formed HIV- 1 RNA (lower limit of detection 20 cp/ml) and HBV DNA 
(lower limit of detection 20 IU/ml) viral load quantification using 
a commercial assay (COBAS®Ampliprep Taqman 96, v2.0, Roche 
Diagnostics GmbH). HBV sequencing was performed in samples of 
patients with HBV DNA >20 IU/ml using previously published meth-
odologies.12 In brief, polymerase was amplified using specific primer 
sets and PCR products were purified with the QIAquick PCR purifi-
cation kit (Qiagen). The Sanger- sequencing reaction was outsourced 
to a commercial service provider (Microsynth AG). Additional labo-
ratory measurements included aspartate aminotransferase (AST), 
alanine aminotransferase (ALT), creatinine and CD4+ cell count. We 
defined ALT as being elevated if ALT >35 IU for men and >25 IU for 
women, according to AASLD recommendations.13 If the HBsAg test 
was positive, the ART regimen was reviewed and replaced by a TDF- 
containing combination if not already prescribed.
We measured liver fibrosis in all HIV/HBV- co- infected individ-
uals using transient elastography (Fibroscan®, Echosens). Liver 
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stiffness measurements (LSM) were performed by a single investi-
gator who received manufacturer- recommended training. Results 
were expressed as the median (kPa) and the interquartile range 
(IQR) of all valid measurements. LSM was considered reliable when 
it included >10 valid measurements with a success rate >60% and 
IQR/M ≤ 0.30.14 Significant liver fibrosis (Metavir stages F2– F4) 
was defined as LSM > 7.1 kPa and cirrhosis (Metavir stage F4) as 
LSM > 11 kPa, as per WHO thresholds.15
2.4  |  Data analysis
Categorical variables were expressed as percentages with 95% con-
fidence intervals (CI), and continuous variables as median values with 
IQR. Demographic and clinical characteristics were compared be-
tween individuals who had been previously tested and others using 
the Mann- Whitney test or Kruskal– Wallis test for continuous vari-
ables and Pearson chi– square (χ2) test or Fisher exact test for cat-
egorical variables. Logistic regression was used to evaluate potential 
associations between patient characteristics and (a) HBV testing up-
take among all PLWH and (b) HBV infection status among individual 
who underwent HBsAg testing. Multivariable models were adjusted 
for age, sex and any other variable with a p- value < 0.05 in univari-
able analyses.
2.5  |  Ethics
The study was approved by the Senegalese National Health Research 
Ethics Committee (CNERS) at the Health and Social Action Ministry 
of Senegal (0061/MSAS/DPRS/CNERS, 576/MSAS/DPRS/CNERS 
and PSS/BTMB/09611). All SEN- B participants signed an informed 
consent.
3  |  RESULTS
3.1  |  Chronic hepatitis B virus testing during 
routine care
Of 1076 PLWH in care for a median of 5.6 years (IQR 2.3– 10.6) at 
the time of the HBV testing intervention, 689 (64.0%) did not have 
a documented HBsAg test in the past (Figure 1). Among 387 indi-
viduals previously tested, 49 (12.4%) were co- infected with HBV. 
Demographic and clinical characteristics of PLWH by HBsAg testing 
status are shown in Table 1 and Table 2. Overall, 158/387 (41.0%) 
men and 229/689 (33.2%) women had been previously tested. In 
multivariable analysis, female patients (adjusted odds ratio (aOR: 
0.70, 95% CI 0.50– 0.98) and those aged >40 years (aOR: 0.55, 
95% CI 0.39– 0.78) were less likely to have been previously tested 
for HBV infection, whereas those who initiated ART after 2014 had 
increased odds of having a known HBV status (aOR: 2.96, 95% CI 
2.12– 4.15; Table 2).
3.2  |  Prevalence and risk factors of chronic 
hepatitis B virus infection
Of 689 previously untested patients, 498 (72.3%) underwent an 
HBsAg test during the HBV testing intervention. Reasons for not test-
ing were the lack of availability of testing kits or reagents in the labora-
tory at time of the visit, unwillingness to participate in the study or not 
attending the follow- up visit, among others. The main demographic 
and clinical characteristics of individuals who were not tested during 
our intervention were similar to those of patients who were tested: 
they were predominantly women (68% vs. 66% among those tested, 
p = 0.63), aged above 40 years old (69% vs. 72%, p = 0.67) and present-
ing with less than 200 CD4 cells/µl (45% vs. 40%; p = 0.01). During the 
F I G U R E  1  Study flow diagram. 
Abbreviations: HBsAg, hepatitis B virus 
antigen; HBV, hepatitis B virus; DNA, 
deoxyribonucleic acid; HIV, human 
immunodeficiency virus; RNA, ribonucleic 
acid
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HBV testing intervention, 58/498 (11.7%) PLWH had a positive HBsAg 
test. Thus, the overall prevalence of HBV infection among PLWH in 
care at our clinic was 12.1% (107 of 884, 95% CI 9.9– 14.3). The preva-
lence of HIV/HBV- co- infection was marginally higher among male 
participants compared to woman (13.6% vs. 11.2%, p = 0.02), whereas 
estimates were similar across age categories (Table 3). In multivariable 
analyses no significant associations were found between potential ex-
planatory variables and HBV infection (Table 4).








Sex (n[%]) Male 227 [33.0] 158 [40.8] 0.02
Female 460 [68.0] 229 [59.2]
Unknown 2 [0.3] 0 [0]
Age, years Median (IQR) 47 [39– 55] 45 [34– 53] <0.001
Employment status (n[%]) Employed 468 [84.8] 299 [77.3] <0.001
Student 33 [6.0] 46 [11.9]
Unemployed 50 [7.3] 15 [3.9]
Unknown 138 [20.0] 27 [7.0]
WHO stage at presentation (n[%]) I– II 228 [33.1] 152 [39.3] <0.001
III– IV 345 [50.1] 215 [55.6]
Unknown 116 [16.8] 20 [5.1]
Period of ART initiation, years (n[%]) 1998– 2013 411 [59.7] 132 [34.1] <0.001
2014– 2019 229 [33.2] 254 [65.6]
Unknown 49 [7.1] 1 [0.3]
CD4 at ART initiation, cel/ul (n[%]) <200 287 [41.7] 187 [48.3] <0.001
200+ 165 [24.0] 129 [33.3]
Unknown 237 [34.4] 71 [18.5]
Time on ART, years Median (IQR) 9,3 [4.8– 12.8] 4,8 [2.5– 8.5] <0.001
ART line regimen (n[%]) 1st line 507 [73.6] 334 [86.3] <0.001
2nd/3rd line 117 [17.0] 47 [12.1]
Unknown 65 [9.4] 6 [1.6]
Abbreviations: ART, Antiretroviral treatment; HBsAg, Hepatitis B virus surface antigen; IQR, interquartile range; WHO, world health organization.
TA B L E  2  Factors associated with HBV testing during routine HIV care
n/N
Univariable analysis Multivariable analysis
OR (95% CI) p OR (95% CI) p
Sex Male 158/385 1.00 0.01 1.00 0.02
Female 229/689 0.72 (0.55– 0.93) 0.71 (0.54– 0.94)
Age group, years 18– 40 149/339 1.00 <0.001 1.00 0.01
>40 237/730 0.61 (0.47– 0.80) 0.69 (0.51– 0.92)
WHO stage at presentation (n[%]) I– II 152/380 1.00 0.62
III– IV 215/560 0.79 (0.57– 1.09)
CD4 at ART initiation, cells/mm3 (n[%]) <200 187/474 1.00 0.23
200+ 129/294 1.19 (0.89– 1.61)
Period of ART initiation, years (n[%]) 1998– 2013 170/632 1.00 <0.001 1.00 <0.001
2014– 2019 213/387 3.33 (2.55– 4.34) 3.02 (2.27– 4.00)
ART line regimen 1st line 334/841 1.00 0.01 1.00 0.26
2nd/3rd line 47/164 0.61 (0.42– 0.88) 0.80 (0.54– 1.18)
Abbreviations: ART, antiretroviral treatment; CI, confidence interval; OR, odds ratio; WHO, world health organization.
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3.3  |  Biological and virological characterization of 
HIV/chronic hepatitis B virus - co- infected individuals
Among 58 individuals who had a newly positive HBsAg test during 
the HBV testing intervention, 55.2% were women and the median age 
was 46 years (IQR 39– 54). These participants were on ART for a me-
dian cumulative time of 7.7 years (IQR 3.0– 11.0) and 30% presented 
to HIV care after 2014, when TDF became available in Senegal. At 
the time of HBV testing intervention, 54 (93.1%) patients were on a 
TDF- containing regimen. Overall, 28/55 (51%) co- infected individuals 
TA B L E  3  Proportion of people living with HIV co– infected with HBV across sub- groups
Characteristics
HIV/HBV Prevalence








WHO stage at presentation
I– II 43/304
III– IV 49/463
CD4 at ART initiation, cel/ul
<200 48/386
200+ 30/238






Abbreviations: ART, antiretroviral treatment; HBV, hepatitis B virus; HIV, human immunodeficiency virus; WHO, World Health Organisation.
TA B L E  4  Correlates for HIV/HBV co- infection
n/N
Univariable analysis Multivariable analysis
OR (95% CI) p OR (95% CI) p
Sex Male 44/323 1.00 0.3 _
Female 63/559 0.81 (0.53– 1.22) _
Age group, years 18– 40 33/281 1.00 0.79 _
>40 74/598 1.06 (0.61– 1.81) _
WHO stage at presentation I– II 43/304 1.00 0.14 _
III– IV 49/463 0.60 (0.36– 1.01) _
CD4 at ART initiation, cel/ul <200 48/386 1.00 0.95 _
200+ 18/153 0.98 (0.52– 1.83) _
Period of ART initiation, years 1998– 2013 53/481 1.00 0.39 _
2014– 2019 45/347 1.20 (0.79– 1.84) _
ART line regimen initiation 1st line 76/688 1.00 0.36 _
2nd/3rd line 18/130 1.29 (0.74– 2.24) _
Abbreviations: ART, antiretroviral treatment; CI, confidence interval; OR, odds ratio; WHO, World Health Organisation.
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(3 individuals had missing creatinine values) had an eGFR (CKD- EPI 
formula) below 90 ml/min/1.73m2, including three with values below 
60 ml/min. One individual had significant liver fibrosis and one liver 
cirrhosis, whereas only one participant had an elevated ALT value 
(Figure 2). Among the 58 HIV/HBV- co- infected individuals, 7 (12.1%) 
had a detectable HBV VL, of whom 5 were HIV- suppressed (Figure 1, 
Figure 2). HBV viral suppression was achieved in 40/47 (85.1%) indi-
viduals on TDF- containing ART and in 1/4 (25.0%) without TDF. HBV 
reverse trancriptase sequencing was successful in 4 of 5 HIV/HBV- 
co- infected individuals with HBV DNA >20 IU/ml, and showed the 
presence of the triple resistance mutation 180 M/204I/80V in two 
patients who were treated with lamivudine as the only HBV- active 
drug (Table 5). The patients without resistance mutations were both 
on a TDF- containing regimen and had never been exposed to lamivu-
dine monotherapy for HBV infection.
4  |  DISCUSSION
In this urban HIV clinic in Senegal, approximately two thirds of PLWH 
had not been tested for the presence of HBV infection during rou-
tine clinical care. Although testing rates increased in recent years, 
they remained sub- optimal, especially among women and older indi-
viduals. During a one- off HBV diagnostic intervention, we screened 
72% of individuals without a previous test and undertook a detailed 
characterization of HIV/HBV- co- infected participants. The overall 
prevalence of HBV infection was 12.1% in our cohort, and the esti-
mate was similar across all sub- groups. Of 58 newly diagnosed cases 
of HBV infection, one- half had some degree of renal dysfunction, 
two patients had significant liver fibrosis or cirrhosis, and 12% had 
detectable HBV DNA levels. Two of four HIV/HBV- co- infected in-
dividuals who were receiving LAM as the only HBV- active drug had 
developed significant drug resistance, which underlines the need for 
the systematic HBsAg testing of PLWH in sub- Saharan Africa.
Despite the importance of HBV testing for the clinical manage-
ment of individuals on ART, our study shows that even in tertiary care 
settings, HBV testing is not a priority in routine clinical care: only 
one third of PLWH on ART had been tested prior to our interven-
tion and that proportion was lower in women and patients aged 40 
and above. The observed gender disparity in access to HBV testing 
was consistent with previous findings from Zambia and Cameroun, 
where men were more likely to be HBsAg screened than women in 
primary and secondary care HIV clinics.16,17 Given the risk of ver-
tical transmission in women with poorly controlled HBV infection, 
F I G U R E  2  Liver, renal and virological assessment of HIV/HBV- co- infected individuals screened during the study. Abbreviations: ALT, 
alanine aminotransferase; eGFR, estimated glomerular filtrate rate; CKD- EPI, chronic kidney disease epidemiology collaboration equation; 
HBV, hepatitis B virus; DNA, deoxyribonucleic acid; HIV, human immunodeficiency virus; RNA, ribonucleic acid; IU, international units
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HBV testing should especially be reinforced in women of childbear-
ing age.18 PLWH were more likely to be tested for HBV infection if 
enrolled into care after 2014, when Senegalese national guidelines 
adopted the WHO recommendations on HBV screening before ART 
initiation and the use of TDF as one of the recommended first- line 
regimens.8,10 As the number of PLWH on second- line regimens is 
increasing in the region, it is crucial to identify those co- infected 
with HBV to maintain TDF as a part of ART.10 Lack of knowledge 
of HBV among health workers19,20 as well as the lack of availabil-
ity of reagents and limited funding for diagnostic tests by national 
programmes are some of the obstacles that need to be addressed in 
order to improve testing uptake in the region.9
Over 90% of newly diagnosed co- infected individuals in our 
study were on a TDF- based regimen for at least 3 years. These es-
timates are higher than those from similar studies in Cameroon and 
the Gambia, where only 60.5% and 11.5% of co- infected individuals 
were on TDF, most likely due to differences in the timing of roll- 
out of TDF in first- line ART across the region.16,21 Despite the use 
of ART including TDF, 9% of co- infected individuals had an HBV 
VL >20 IU/ml at the time of assessment, the majority being HIV- 
suppressed. Our results are in line with those from a small prospec-
tive study in Ivory Coast: among 86 HIV/HBV- co- infected patients 
on TDF- containing ART, 94.2% had a suppressed HBV VL after a 
median of 35 months.22 Whereas it remains unclear why a minority 
of patients experiences continuous HBV replication on TDF despite 
HIV suppression, a number of risk factors have been described, in-
cluding sub- optimal treatment adherence, severe immunosuppres-
sion and HBeAg status at ART initiation.23 Importantly, only two 
patients on long- term TDF- containing ART had a LSM compatible 
with significant liver fibrosis or cirrhosis in our study. These findings 
add to the increasing body of literature from SSA showing that po-
tent HBV treatment is associated with a long- term reduction in liver 
fibrosis progression among HIV/HBV- co- infected individuals.5,24
Of four individuals newly diagnosed with chronic HBV infection 
who had never been exposed to TDF, two had HBV replication on 
a regimen including LAM and AZT. Sequencing of the polymerase 
showed the presence of LAM- associated resistance mutations in 
both patients (one with genotype A1 and the other with genotype E). 
These findings underline the high likelihood of resistance develop-
ment during LAM HBV monotherapy, as shown in previous studies 
in the region. In cohort analyses from Cameroun, Malawi and South 
Africa, the use of LAM without TDF was linked to the gradual emer-
gence of resistance mutations in the HBV polymerase gene.25– 27 The 
proportion of individuals with detectable HBV VL on LAM mono-
therapy who developed resistance reached 88% in an HIV cohort 
from The Gambia.20 Given the significant proportion of participants 
who were on a sub- optimal ART regimen for HBV therapy and the 
related virological and clinical consequences, our data highlight the 
importance of the systematic HBsAg testing of all PLWH entering 
care and initiating ART.
The use of TDF has been associated with proximal renal tubulop-
athy, which is of special concern for HIV/HBV- co- infected individuals 
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studies on renal function trajectories in PLWH in SSA to date, indi-
viduals on TDF were three times more likely to develop moderate or 
severe renal dysfunction compared to those on other NRTI, but the 
incidence of severe renal dysfunction events was low.28 In our study, 
more than half of HIV/HBV- co- infected individuals showed some de-
gree of renal dysfunction (eGFR < 90 ml/min/1.73m2) while on ART, 
but only 5% had an eGFR below 60 ml/min/1.73m2. HBV infection 
has been identified as a predictor of progressive renal impairment in 
PLWH.29 In Zambia, PLWH co- infected with HBV were twice as likely 
to have severe renal dysfunction as those who were HBV- negative.30 
As life expectancy among African PLWH is increasing, their risk of 
developing cardio- metabolic complications and associated renal dys-
function is higher.31 Thus, data on long- term renal outcomes from 
prospective cohorts of ageing PLWH co- infected with HBV in SSA 
are urgently needed to inform future treatment guidelines and the 
potential benefit of replacing TDF by TAF.32
Our study is among the first to provide comprehensive HBV 
virological data from HIV/HBV- co- infected individuals in West 
Africa, and illustrates how a simple diagnostic intervention can help 
improve the control of HBV infection in a busy urban HIV clinic. 
Unfortunately, we were unable to include one quarter of individu-
als without a previous HBsAg test, mainly due to logistical reasons. 
As the demographic characteristics of individuals not included 
in the study did not differ significantly from those of our partici-
pants, and given the stable prevalence of HBV infection across sub- 
populations, we do not anticipate a significant selection bias. Given 
that our analysis of renal dysfunction relied on a single creatinine 
measurement, we were not able to differentiate acute from chronic 
renal injury and may have over- estimated the true burden of renal 
impairment in our cohort. Finally, we may have under- estimated the 
prevalence of HBV treatment failure with emerging drug resistance 
as we were not able to sequence the virus of each individual with 
detectable VL during ART.
5  |  CONCLUSIONS
In this urban West African referral HIV clinic, the majority of PLWH 
on ART never had an HBV test performed during routine care. 
Among newly diagnosed HBV- co- infected individuals, one in ten had 
a detectable HBV viral load despite HIV suppression, and 8% were 
not receiving a TDF- containing regimen. Considering the increased 
risk of liver- related complication in individuals with HBV replication 
and the beneficial impact of TDF on reducing their incidence, HBV 
testing should be performed routinely during HIV clinical care. The 
early diagnosis of HBV infection should trigger additional investiga-
tions, including the evaluation of liver fibrosis and the initiation of 
HCC screening among high- risk patients. As the wider implementa-
tion of simple diagnostic interventions, such as HBsAg testing and 
reflex liver fibrosis evaluation, could help reduce liver- related com-
plications among PLWH in sub- Saharan Africa, their feasibility and 
cost- effectiveness should be urgently evaluated in large, prospec-
tive cohort settings.
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